INBP · Integrated Biopharma Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q3 '26 | Q2 '26 | Q1 '26 | Q2 '25 | Q3 '25 | Q1 '25 | Q2 '24 | Q3 '24 | Q1 '24 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | $10.38M | $11.25M | $11.67M | $11.44M | $12.40M | $12.25M | $10.99M | $11.90M | $12.08M | $11.18M |
| Gross Profit | ($276.0K) | $29.0K | $1.02M | $1.17M | $1.55M | $1.37M | $520.0K | $1.25M | $832.0K | $1.07M |
| R&D | - | - | - | - | - | - | - | - | - | - |
| SG&A | $809.0K | $943.0K | $856.0K | $969.0K | $812.0K | $881.0K | $972.0K | $893.0K | $886.0K | $1.10M |
| Total Operating Expenses | - | - | - | - | - | - | - | - | - | - |
| D&A | $68.0K | $78.0K | $77.0K | $83.0K | $76.0K | $88.0K | $78.0K | $77.0K | $77.0K | $93.0K |
| Operating Income | ($1.08M) | ($914.0K) | $163.0K | $202.0K | $739.0K | $490.0K | ($452.0K) | $355.0K | ($54.0K) | ($33.0K) |
| Interest Expense | ($39.0K) | ($40.0K) | ($33.0K) | ($2.0K) | $4.0K | ($14.0K) | ($2.0K) | $4.0K | ($8.0K) | $12.0K |
| Income Tax | ($198.0K) | ($112.0K) | $73.0K | $69.0K | $167.0K | $245.0K | ($70.0K) | $67.0K | $13.0K | $10.0K |
| Net Income | ($837.0K) | ($762.0K) | $123.0K | $116.0K | $611.0K | $259.0K | ($382.0K) | $285.0K | ($59.0K) | ($55.0K) |
| EPS - Basic | ($0.03) | ($0.03) | $0.00 | $0.00 | $0.02 | $0.01 | ($0.01) | $0.01 | $0.00 | $0.00 |
| EPS - Diluted | ($0.03) | ($0.03) | $0.00 | ($0.01) | $0.02 | $0.01 | - | $0.01 | - | $0.03 |
Balance Sheet
| Line item | Q3 '26 | Q2 '26 | Q1 '26 | Q2 '25 | Q3 '25 | Q1 '25 | Q2 '24 | Q3 '24 | Q1 '24 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $5.83M | $5.31M | $4.73M | $3.62M | $2.96M | $2.27M | $1.68M | $2.02M | $2.59M | $1.32M |
| Accounts Receivable | $3.65M | $3.59M | $3.98M | $5.43M | $5.08M | $4.38M | $4.67M | $4.72M | $4.17M | $4.51M |
| Inventory | $8.12M | $8.36M | $10.47M | $9.36M | $10.08M | $11.22M | $11.24M | $11.17M | $10.51M | $10.26M |
| Accounts Payable | $2.96M | $2.14M | $2.80M | $2.27M | $2.50M | $2.76M | $2.51M | $3.67M | $3.54M | $2.27M |
| Current Assets | $17.97M | $17.82M | $19.62M | $18.76M | $18.55M | $18.31M | $17.88M | $18.26M | $17.76M | $16.37M |
| Total Assets | $26.67M | $23.55M | $25.54M | $24.90M | $25.66M | $26.18M | $26.21M | $26.94M | $26.64M | $25.43M |
| Current Liabilities | $5.53M | $3.54M | $4.76M | $4.25M | $4.98M | $6.03M | $6.12M | $6.95M | $6.20M | $4.83M |
| Long-term Debt | - | - | - | - | - | - | - | $0 | - | $7.0K |
| Total Liabilities | $7.69M | $3.78M | $5.05M | $4.58M | $5.27M | $6.63M | $6.97M | $8.03M | $7.76M | $6.57M |
| Stockholders' Equity | $18.98M | $19.77M | $20.49M | $20.32M | $20.38M | $19.55M | $19.24M | $18.91M | $18.89M | $18.86M |
| Retained Earnings | ($32.90M) | ($32.06M) | ($31.30M) | ($31.42M) | ($31.24M) | ($31.97M) | ($32.23M) | ($32.49M) | ($32.40M) | ($32.34M) |
Cash Flow
| Line item | Q3 '26 | Q2 '26 | Q1 '26 | Q2 '25 | Q3 '25 | Q1 '25 | Q2 '24 | Q3 '24 | Q1 '24 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | $1.30M | - | - | $657.0K | - | - | $1.31M | - |
| Investing Cash Flow | - | - | ($173.0K) | - | - | ($56.0K) | - | - | ($38.0K) | - |
| Financing Cash Flow | - | - | ($11.0K) | - | - | ($7.0K) | - | - | $3.0K | - |
| CapEx | - | - | $173.0K | - | - | $56.0K | - | - | $38.0K | $32.0K |
| Free Cash Flow | - | - | $1.13M | - | - | $601.0K | - | - | $1.27M | - |
Ratios
| Metric | Q3 '26 | Q2 '26 | Q1 '26 | Q2 '25 | Q3 '25 | Q1 '25 | Q2 '24 | Q3 '24 | Q1 '24 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | 9.17 | - | - | 2.32 | - | - | -21.61 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | 37.2% | 37.3% | 21.5% | 48.6% | - | 19.0% | - | - |
| Return on assets | -3.1% | -3.2% | 0.5% | 0.5% | 2.4% | 1.0% | -1.5% | 1.1% | -0.2% | -0.2% |
| Return on equity | -4.4% | -3.9% | 0.6% | 0.6% | 3.0% | 1.3% | -2.0% | 1.5% | -0.3% | -0.3% |
| Return on invested capital | - | - | - | - | - | - | - | 1.5% | - | -0.1% |
| Liquidity | ||||||||||
| Current ratio | 3.25 | 5.03 | 4.12 | 4.42 | 3.72 | 3.04 | 2.92 | 2.63 | 2.87 | 3.39 |
| Quick ratio | 1.78 | 2.67 | 1.92 | 2.21 | 1.70 | 1.18 | 1.08 | 1.02 | 1.17 | 1.27 |
| Cash ratio | 1.05 | 1.50 | 0.99 | 0.85 | 0.59 | 0.38 | 0.27 | 0.29 | 0.42 | 0.27 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | 0.00 | - | 0.00 |
| Debt / Assets | - | - | - | - | - | - | - | 0.00 | - | 0.00 |
| Debt / EBITDA | - | - | - | - | - | - | - | 0.00 | - | 0.12 |
| Interest coverage | 27.8x | 22.9x | -4.9x | -101.0x | 184.8x | -35.0x | 226.0x | 88.8x | 6.8x | -2.8x |
| Equity multiplier | 1.40 | 1.19 | 1.25 | 1.23 | 1.26 | 1.34 | 1.36 | 1.42 | 1.41 | 1.35 |
| Liabilities / Assets | 0.29 | 0.16 | 0.20 | 0.18 | 0.21 | 0.25 | 0.27 | 0.30 | 0.29 | 0.26 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | 1.28 | 1.35 | 1.11 | 1.22 | 1.23 | 1.09 | 0.98 | 1.07 | 1.15 | 1.09 |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | 285d | 271d | 327d | 299d | 297d | 335d | 373d | 343d | 318d | 335d |
| Days payable outstanding | 104d | 70d | 88d | 72d | 74d | 82d | 83d | 113d | 107d | 74d |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | -97.5% | -25.7% | 125.2% | 24.3% | 64.8% | -51.4% | 23.8% | -16.5% | -38.9% |
| Operating income growth (YoY) | - | - | -66.7% | - | 108.2% | - | -1269.7% | 706.8% | - | - |
| Net income growth (YoY) | - | - | -52.5% | - | 114.4% | - | -594.5% | 1681.3% | -68.6% | - |
| EPS growth (YoY) | - | -200.0% | - | - | 100.0% | - | - | - | - | 0.0% |
| EPS CAGR (3y) | - | - | - | - | -12.6% | - | - | -37.0% | - | 0.0% |
| EPS CAGR (5y) | - | - | - | - | -7.8% | 0.0% | - | -19.7% | - | - |
| FCF growth (YoY) | - | - | 87.7% | - | - | -52.9% | - | - | 35.4% | - |
| FCF CAGR (5y) | - | - | -10.6% | - | - | -18.1% | - | - | 17.3% | - |
| Book value growth (YoY) | -6.9% | -2.7% | 4.8% | 5.6% | 7.8% | 3.5% | 2.0% | 0.9% | 1.4% | 1.5% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing INTEGRATED BIOPHARMA INC against the 5 most active filers in the same SIC group.